Is Telomir Pharmaceuticals, Inc. (TELO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 2.9% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 2.9% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 95.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 2.9% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 95.6% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -317.6% | |
| Return on Assets (ROA) | -152.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$5M |
| Free Cash Flow | -$5M |
| Debt-to-Equity | 8.0 |
| Current Ratio | 5.1 |
| Total Assets | $1M |
Price & Trading
| Last Close | $1.26 |
| 50-Day MA | $1.26 |
| 200-Day MA | $1.44 |
| Avg Volume | 138K |
| Beta | -0.7 |
|
52-Week Range
$1.05
| |
About Telomir Pharmaceuticals, Inc. (TELO)
Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Wilson's disease, Type 2 diabetes, age-related macular degeneration (AMD), oncology, and epigenetic regulation, as well as Alzheimer's disease and Progeria. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Miami, Florida.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Telomir Pharmaceuticals, Inc. (TELO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Telomir Pharmaceuticals, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Telomir Pharmaceuticals, Inc.'s debt ratio?
Telomir Pharmaceuticals, Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Telomir Pharmaceuticals, Inc.'s key financial metrics?
Telomir Pharmaceuticals, Inc. has a market capitalization of $43M. Return on equity stands at -317.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.